Finasteride vs Dutasteride for Hair Loss: 2026 Evidence

Finasteride and dutasteride can both improve male androgenetic alopecia. Dutasteride has produced larger average gains in some studies, but it has not been superior in every head-to-head trial. Choosing between them requires consideration of hair-loss severity, response to prior treatment, adverse-effect risk, pregnancy-related exposure precautions, and each country's approved uses.^{2014-trial2019-meta2026-trial}

Finasteride and dutasteride at a glance

Feature	Finasteride	Dutasteride
Main enzyme target	Primarily inhibits type II 5-alpha-reductase	Inhibits type I and type II 5-alpha-reductase
Dose used in major comparisons	Usually 1 mg daily	Usually 0.5 mg daily
DHT suppression	Less extensive	More extensive
Evidence in male pattern hair loss	More long-term treatment data	Some direct trials and meta-analyses show larger hair gains
Shared cautions	Sexual adverse effects and pregnancy-exposure precautions	Sexual adverse effects and pregnancy-exposure precautions

Both drugs inhibit 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT). DHT contributes to miniaturization of genetically susceptible scalp follicles. Dutasteride's broader enzyme inhibition does not automatically make it the right choice for every person.^{2014-trialguidance}

The 2026 head-to-head trial found no efficacy difference

A randomized, single-blind Iranian study published online in 2026 compared finasteride 1 mg daily with dutasteride 0.5 mg daily for 24 weeks in 46 men with moderate-to-severe androgenetic alopecia.^2026-trial

Both groups improved, with no statistically significant difference in hair-growth outcomes or satisfaction at 24 weeks. PSA declined more in the dutasteride group, consistent with stronger 5-alpha-reductase inhibition. Safety profiles were similar, and no serious adverse events were reported.^2026-trial

This small study does not prove that the treatments are equivalent. It enrolled only 46 participants in one region and followed them for 24 weeks. It was too small and short to assess uncommon adverse events or longer-term differences reliably.

Earlier evidence favored dutasteride

In a 2014 randomized active- and placebo-controlled trial of 917 men, dutasteride 0.5 mg daily produced larger improvements than finasteride 1 mg daily at 24 weeks in hair count, hair width, and photographic assessment. The number and severity of overall adverse events were similar across treatment groups.^2014-trial

A 2019 meta-analysis pooled three direct randomized comparisons with 576 participants. Dutasteride performed better for total hair count and several vertex and frontal photographic assessments over 24 weeks. Differences between drugs in altered libido, erectile dysfunction, and ejaculation disorders were not statistically significant.^2019-meta

Differences in sample size, baseline severity, scalp area, measurement methods, and adherence may help explain why trials do not all reach the same result. The overall evidence supports the possibility of greater average efficacy with dutasteride, but it does not guarantee a better outcome—or identical risk—for every patient.

What about intermittent dutasteride?

A 2025 pilot trial randomized 60 men to dutasteride 0.5 mg twice weekly, dutasteride 0.5 mg three times weekly, or finasteride 1 mg daily for 24 weeks. Hair density and diameter increased in all groups. Three-times-weekly dutasteride outperformed twice-weekly dosing, but did not produce a statistically significant hair-count advantage over daily finasteride.^{intermittent-trial}

This pilot does not authorize self-directed dose changes. Dutasteride remains in the body for a long time, and any change in dose or schedule should be discussed with the prescriber.

Which drug has fewer side effects?

Both medicines can be associated with changes in libido, erection, or ejaculation. A 2019 meta-analysis of 15 double-blind placebo-controlled trials involving 4,495 participants found that 5-alpha-reductase inhibitors as a group were associated with increased sexual-dysfunction risk. The increase was statistically significant for finasteride; evidence for dutasteride was less certain because fewer dutasteride studies were available.^{sexual-ae-meta}

A nonsignificant difference between the drugs in a head-to-head study does not mean there is no risk. Discuss relevant symptoms and medical history before treatment, and contact the prescriber if a change occurs instead of switching or stopping medication without guidance.

Both medicines can also lower PSA. Tell the clinician interpreting a prostate test that you take a 5-alpha-reductase inhibitor. The 2026 comparison found a larger PSA decrease in the dutasteride group.^2026-trial

Women and pregnancy-related precautions

The central comparative trials in this article enrolled adult men; their findings should not simply be applied to female pattern hair loss. Finasteride and dutasteride can pose a risk to a male fetus, so people who are or may be pregnant should avoid exposure. Product-specific instructions include precautions around handling broken or crushed dosage forms.^{finasteride-labeldutasteride-label}

How should the choice be made?

The decision should not be reduced to these claims:

• “Dutasteride is stronger, so it is always better.”
• “Finasteride has been used longer, so it has no adverse effects.”
• “Lowering the dose without advice solves the risk.”
• “If one drug is inadequate, taking both must be better.”

A more useful approach is to confirm the diagnosis and severity, record a reproducible baseline with standardized photographs or measurements, and assess response over an agreed interval. When changing treatment, the duration, adherence, benefit, and adverse effects of the prior medicine all matter.

For the older brand- and mechanism-focused overview, see Avodart vs Propecia. This new article focuses on direct comparative evidence available through 2026 rather than repeating that page.

Frequently asked questions

Does dutasteride regrow more hair than finasteride?

Some larger trials and a meta-analysis found greater average improvement with dutasteride 0.5 mg. A small 2026 comparison found no significant efficacy difference at 24 weeks. Neither result predicts an individual's outcome with certainty.^{2014-trial2019-meta2026-trial}

When can treatment response be judged?

Many direct comparisons assessed their main outcomes at 24 weeks. Clinical follow-up may need to be longer depending on progression and the treatment plan, so standardized baseline and follow-up photographs are useful.

Should someone switch to dutasteride if finasteride causes no side effects?

Absence of side effects is only one consideration. Current response, treatment duration, disease severity, medical history, monitoring, and approved indications should be reviewed with the prescriber.

Are these medicines used after a hair transplant?

Medical treatment may be considered because nontransplanted hair can continue to miniaturize. It is not identical for everyone; see Hair-Loss Medication After a Hair Transplant for a focused discussion.

Bottom line

Dutasteride has shown stronger DHT suppression and larger average hair improvements in some studies, while the latest small trial found no significant efficacy difference from finasteride. This is not simply a choice of the “stronger” drug. Diagnosis, response, adverse-effect risk, monitoring, and local approvals should guide a shared decision with a qualified clinician.

Sudden, patchy, painful, inflamed, scarring, or rapidly worsening hair loss should be evaluated by a dermatologist rather than self-diagnosed as male pattern hair loss.